ReviewCancers2020

Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies.

Alberto D'Angelo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.